Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

3.3%

2 terminated/withdrawn out of 61 trials

Success Rate

93.3%

+6.7% vs industry average

Late-Stage Pipeline

3%

2 trials in Phase 3/4

Results Transparency

29%

8 of 28 completed trials have results

Key Signals

17 recruiting8 with results

Enrollment Performance

Analytics

N/A
24(46.2%)
Phase 1
14(26.9%)
Phase 2
11(21.2%)
Phase 4
2(3.8%)
Early Phase 1
1(1.9%)
52Total
N/A(24)
Phase 1(14)
Phase 2(11)
Phase 4(2)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (61)

Showing 20 of 61 trials
NCT03690011Phase 1Active Not Recruiting

Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells

Role: collaborator

NCT05672927Phase 4Recruiting

Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)

Role: collaborator

NCT07783659Phase 1Not Yet Recruiting

Zotatifin And EIF4A Platinum Helix Inhibition In Resistant AdvancedTNBC

Role: collaborator

NCT05402033Recruiting

Cancer Clinical Trials Financial Reimbursement Program

Role: collaborator

NCT07586618Phase 1Recruiting

First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.

Role: collaborator

NCT07753824Phase 2Not Yet Recruiting

A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA)

Role: collaborator

NCT02494167Phase 1Completed

Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM)

Role: collaborator

NCT06284564Phase 2Active Not Recruiting

A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)

Role: collaborator

NCT07382583Recruiting

Development of a Shared Decision Tool to Facilitate Uptake of the Levonorgestrel-releasing Intrauterine System for the Primary Prevention of Endometrial Cancer

Role: collaborator

NCT05196867Not ApplicableActive Not Recruiting

Liver Cancer Prevention Randomized Control Trial

Role: collaborator

NCT07186556Not ApplicableRecruiting

Cancer-related Fatigue and Its Biological Contributors in Adolescent and Young Adult Brain Tumor Survivors: Effects of a Tele-exercise Intervention

Role: collaborator

NCT07010315Recruiting

Development and Testing of a Patient-facing Educational Tool About Liver Cancer Prevention

Role: collaborator

NCT06665100Phase 2Recruiting

PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)

Role: collaborator

NCT04099797Phase 1Recruiting

C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)

Role: collaborator

NCT06004336Phase 2Recruiting

A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs)

Role: collaborator

NCT05113927Not ApplicableCompleted

Wide Field OCT + AI for Positive Margin Rates in Breast Conservation Surgery.

Role: collaborator

NCT03635632Phase 1Active Not Recruiting

C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)

Role: collaborator

NCT05724563Phase 2Active Not Recruiting

Domvanalimab and Zimberelimab in Advanced Liver Cancers

Role: collaborator

NCT04614194Phase 2Recruiting

Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib

Role: collaborator

NCT03080090Not ApplicableCompleted

YMCA Exercise Intervention for Smoking Cessation Study

Role: collaborator